The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis

    loading  Checking for direct PDF access through Ovid

Abstract

Background:

Major advances have been made in the understanding of the pathophysiology of psoriasis.

Objectives:

The authors review the role of interleukin (IL) 17 in the pathogenesis of psoriasis and provide updates on approved and investigational therapies targeting IL-17 and the IL-17 receptor.

Methods:

A PubMed search was performed for relevant literature.

Conclusion:

The IL-23/Th17 signaling pathway (including IL-17) plays a central role in the pathogenesis of psoriasis. Biologic agents that block IL-17 (secukinumab and ixekizumab) or its receptor (brodalumab) are effective and safe for the treatment of psoriasis.

Related Topics

    loading  Loading Related Articles